
SOLUTIONS FOR PATIENTS & PROVIDERS
Viventis is shaping the future of cancer treatment by integrating AI, genomic insights, and patient-centric care. Explore how our solutions are making a difference in oncology today.


FOR PATIENTS
Viventis is dedicated to empowering patients with personalized, AI-driven cancer care solutions. Our technology ensures tailored treatment strategies and access to cutting-edge therapies.
Personalized Treatment Plans: AI-driven insights help design individualized cancer treatment strategies for better outcomes.
Clinical Trial Matching with AI: Our platform connects patients with relevant clinical trials, increasing access to innovative therapies.
Support & Patient Resources: Comprehensive educational tools, support groups, and expert consultations help patients navigate their treatment journey with confidence.


FOR ONCOLOGISTS
Viventis enhances oncologists' capabilities with advanced AI-driven decision-making tools, streamlining treatment planning and improving patient care.
AI-Driven Treatment Recommendations: Our platform provides oncologists with real-time, data-backed treatment insights for precise cancer care.
Real-Time Genomic Insights: Advanced genomic analytics offer personalized insights, optimizing therapy selection for each patient.
Integration with Hospital Systems: Seamless compatibility with electronic health records (EHRs) and hospital management systems ensures effortless adoption and workflow enhancement.


FOR BIOPHARMA & RESEARCHERS
Viventis accelerates the pace of drug discovery and clinical research by leveraging AI and real-world oncology data.
Accelerated Drug Discovery: AI-powered analytics streamline target identification, drug formulation, and preclinical studies
Access to Real-World Oncology Data: Secure access to extensive patient data sets enhances research capabilities and drug development.
AI-Driven Clinical Trial Optimization: Our platform improves trial efficiency by identifying optimal patient cohorts, reducing dropout rates, and increasing trial success rates.
